DOCSLIB.ORG

II.4.9 Treatment of Sexual Dysfunction L.J.G

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
II.4.9 Treatment of Sexual Dysfunction L.J.G 528 II.4 Therapeutic Options DM (1998) Metastatic prostatic carcinoma in a male-to- vanKesterenP,LipsP,GoorenLJ,AsschemanH,MegensJ female transsexual. Br J Urol 81:776 (1998) Long-term follow-up of bone mineral density and van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ (1997) bone metabolism in transsexuals treated with cross-sex hor- Mortality and morbidity in transsexual subjects treated with mones. Clin Endocrinol (Oxf) 48:347–354 cross-sex hormones. Clin Endocrinol (Oxf) 47:337–342 II.4.9 Treatment of Sexual Dysfunction L.J.G. Gooren Summary function does not necessarily imply restoration of a The introduction of the phosphodiesterase type 5 happy sex life (Montorsi and Althof 2004). Neverthe- inhibitors (PDE inhibitors) has been a major step less, the introduction of the phosphodiesterase type 5 forward in the treatment of erectile dysfunction inhibitors has substantially improved the therapeutic (ED). Though efficacious and safe, 50% of men options for ED. discontinue treatment, largely because other sexo- logical issues have not been properly addressed. To II.4.9.1.1 predict onset and duration of action, insight into Phosphodiesterase Type 5 Inhibitors the pharmacokinetics of the PDE inhibitors is re- quired. The identification of pathways in the physiology of erection and the discovery of the importance of nitric ■ In men whose testosterone levels are low, oxide (NO) and its downstream effects lie at the basis of testosterone substitution may booster the effi- the development of the phosphodiesterase type 5 in- cacy of PDE inhibitors. hibitors (PDE inhibitors). Subsequent to sexual stimu- ■ Before receiving PDE inhibitor the cardiovas- lation, NO arising from the nerve endings of non-ad- cular status of a patient must be assessed. renergic non-cholinergic innervation of the corpus ca- Themainactionoftestosteroneisonthecentral vernosum activates guanylyl cyclase, an enzyme that nervous system. It improves libido and mood. catalyses the conversion of GTP to cGMP.At the cellular Levels in the low-normal range suffice. level cGMP is broken down to 5-GMP by phosphodies- Hyperprolactinaemia impairs sexual interest terase type 5. Via a molecular cascade cGMP lowers in- and leads to secondary ED. Dopamine agonists are tracellular calcium and vascular smooth muscle of the the treatment of choice. corpus cavernosum relaxes, resulting in an increased Men with paraphilias may be treated with drugs penile blood flow thus facilitating the initiation and that lower androgen action if the desire to act out maintenance of an erection. their paraphilia is high. The pharmacological action of PDE inhibitors man- ifests itself only when a person is sexually aroused, which distinguishes this class of drugs from intracaver- II.4.9.1 nosal injections. This is also important information for the user (Seftel 2004). Erectile Dysfunction The efficacy and relative safety of PDE inhibitors is The availability of a highly efficacious and relatively well documented now. They have a common mode of safe compound such as the phosphodiesterase type 5 action, the inhibition of PDE 5. Selectivity and tissue inhibitor sildenafil has had a profound impact on diag- localization of the PDE inhibitors determine the side- nosis and treatment of erectile dysfunction (ED). Once effect profiles and safety. the domain of the urologist attempting to define the There are presently three PDE inhibitors available precise aetiology, ED is now largely treated by first-line for prescription: sildenafil, vardenafil and tadalafil. All physicians, without much of a diagnostic work-up. De- are efficacious, but there are differences in pharmaco- spite the simplicity and safety of the present therapy of kinetic profile, interactions with food and drugs, and ED, approximately 50% of patients discontinue treat- possible side-effects. Taking nitrate medications is an ment. The reasons for discontinuations lie mostly in an absolute contraindication to the use of PDE inhibitors incomplete evaluation of the sexual problem. Hypo- since PDE inhibitors increase the potential for exces- gonadism, ejaculatory dysfunction, lower urinary tract sively low blood pressure. Low blood pressure, though symptoms, depression, and last but not least partner is- to a lesser degree, has also been observed with PDE in- II.4 sues may all be components of the sexual dysfunction hibitors in men taking alpha adrenoreceptor antago- of the patient, and apparently restoration of erectile nists, such as doxazosin, prazosin, terazosin, alfuzosin II.4.9 Treatment of Sexual Dysfunction 529 ortamsulosin,whichareusedasantihypertensive It is not rare for patients to wish to “experiment” agents or for symptomatic relief of lower urinary tract with the available PDE inhibitors to find the drug that symptoms (LUTS). The latter is relevant since sexual suits them best. Patients do have distinctly different dysfunction is not rare in men with LUTS, both signifi- sexual habits with regard to timing of sexual activity. cantly increasing with age, and possibly sharing aetio- Another consideration is the “readiness” of the patients logical factors (Rosen et al. 2003). Drugs such as eryth- when sexual activity is initiated by the partner. romycin, ketoconazole and itraconazole, and protease The above information on dose–response effects inhibitors used in HIV treatment such as saquinavir, (sildenafil and tadalafil), the interaction with (particu- indinavirandritovirmayslowlivermetabolismofPDE larly fat-rich) food in slowing absorption, and the inhibitors and may increase plasma levels and the effect pharmacokinetic profiles may provide guidance. Pa- of PDE inhibitors. Grapefruit juice may have a similar tients who, in a series of at least four attempts to have effect on liver metabolism. Lower doses must be used in intercourse, do not respond to the maximum dose of patients with liver and/or kidney disease. one of the PDE inhibitors are unlikely to respond to the Sildenafil and vardenafil work best if no (fatty) food others. has been taken within the previous 2 h, while tadalafil Naturally, patients starting treatment with a PDE in- can be used without regard to food. hibitor will experience some anxiety about whether the Common adverse effects attributable to vasodilato- new drug will indeed induce an erection. Anxiety may ry effects include headache, flushing, stuffy nose, stom- reduce sexual arousal, which is a necessary condition ach pain, back pain (tadalafil) and indigestion. Visual for the desired pharmacological action of PDE inhibi- problems (for example, blurred vision, increased sensi- tors. Therefore, in case the patient recognizes this as a tivity to light, bluish haze, or temporary difficulty dis- potential problem, testing the efficacy of the drug first tinguishing between blue and green) may occur, more with masturbation may be recommended. often with sildenafil since the latter is less selective in At least 50% of patients suffering from ED have en- inhibiting phosphodiesterase 6 in the retina. dothelial dysfunction, and there are early indications Theprescribedtabletstrengthisswallowed that chronic treatment with PDE inhibitors might im- 30–60 min before sexual activity. Tadalafil has a longer prove their vascular function (Jackson 2003; Reffel- duration of increased sensitivity for developing an mann and Kloner 2003). At the same time chronic use erection (up to 24–36 h) compared with sildenafil and would obviate the need to take a PDE inhibitor before vardenafil (up to 4–12 h). engaging in sexual activity. There is no convincing evidence that the three avail- able PDE inhibitors differ significantly in their clinical II.4.9.1.2 efficacy. For sildenafil (50 and 100 mg) and tadalafil PDE Inhibitors and the Cardiovascular System (10 and 20 mg) there is a dose–response relationship, whichisnotsomuchthecaseforvardenafil(10and When the first PDE inhibitor sildenafil was introduced 20 mg) (Carson et al. 2004). In general starting with the there was great concern about the cardiovascular safety lowest dose of PDE inhibitors is recommended. of this class of drugs. In many a patient the aetiology of The feature that distinguishes the three PDE inhibi- ED is (also) based on vascular disease. The availability tors is their pharmacokinetic profile, which impacts on ofthedrugpromptedpatientstoresumesexualactivity their clinical use, in terms of the initiation of optimal after prolonged periods of inactivity. The pharmaco- pharmacological effect and duration of pharmacologi- logical action of PDE inhibitors is vasodilatory. Fears cal action [for review see Porst (2004)]. The time to arose that these elements would lead to myocardial is- maximal plasma concentration (in minutes) is on aver- chaemia or infarction when intercourse was attempted. age 60 (variation 30–120) for sildenafil, 120 (variation Fortunately,theseconcernshaveremainedunsubstan- 30–720!) for tadalafil and 60 (variation 30–120) for tiated. Placebo-controlled studies fail to show a higher vardenafil. These are statistical data and individual pa- cardiovascular morbidity/mortality in patients using tients may experience a faster onset of action. This in- PDE inhibitors (Hutter 2004; Kloner 2004). Naturally, formation lets patients plan prospective sexual action. before starting PDE inhibitors, the cardiovascular risks Another significant pharmacokinetic variable is the of the patient must be assessed. Factors such as hyper- half-life of the drug, which provides an indication of tension, biochemical risk markers, angina pectoris, ar- how long the
Load more

Recommended publications
  • Hypersexuality in Neurological Disorders
    HYPERSEXUALITY IN NEUROLOGICAL DISORDERS NATALIE AHMAD MAHMOUD TAYIM A thesis submitted to the Institute of Neurology in fulfilment of the requirements for the degree of Doctor of Philosophy (PhD) University College London January 2019 Declaration of originality I, Natalie Ahmad Mahmoud Tayim, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. _________________________________ Natalie Ahmad Mahmoud Tayim ii Abstract The issue of hypersexuality in neurological disorders is grossly underreported. More research has been done into sexual dysfunction (outside of hypersexuality) in neurological disorders such as erectile dysfunction and hyposexuality (loss of libido). Furthermore, in Parkinson’s disease research, most mention of hypersexuality has been in conjunction with other impulse control disorders and has therefore not been examined in depth on its own. Although in recent years hypersexuality has become more recognized as an issue in research, there is still very limited information regarding its manifestations, impact, and correlates. It is therefore important to explore this area in detail in order to broaden understanding associated with this sensitive issue. Perhaps in doing so, barriers will be broken and the issue will become more easily discussed and, eventually, more systematically assessed and better managed. This thesis aims to serve as an exploratory paper examining prevalence, clinical phenomenology, impact, and potential feasible psychological interventions for hypersexuality in patients with neurological disorders and their carers. The thesis is divided into three main studies: 1. Study I: systematic review assessing prevalence, clinical phenomenology, successful treatment modalities, implicated factors contributing to the development, and assessment tools for hypersexuality in specific neurological disorders.
    [Show full text]
  • Sexual Disorders and Gender Identity Disorder
    CHAPTER :13 Sexual Disorders and Gender Identity Disorder TOPIC OVERVIEW Sexual Dysfunctions Disorders of Desire Disorders of Excitement Disorders of Orgasm Disorders of Sexual Pain Treatments for Sexual Dysfunctions What are the General Features of Sex Therapy? What Techniques Are Applied to Particular Dysfunctions? What Are the Current Trends in Sex Therapy? Paraphilias Fetishism Transvestic Fetishism Exhibitionism Voyeurism Frotteurism Pedophilia Sexual Masochism Sexual Sadism A Word of Caution Gender Identity Disorder Putting It Together: A Private Topic Draws Public Attention 177 178 CHAPTER 13 LECTURE OUTLINE I. SEXUAL DISORDERS AND GENDER-IDENTITY DISORDER A. Sexual behavior is a major focus of both our private thoughts and public discussions B. Experts recognize two general categories of sexual disorders: 1. Sexual dysfunctions—problems with sexual responses 2. Paraphilias—repeated and intense sexual urges and fantasies to socially inappropri- ate objects or situations C. In addition to the sexual disorders, DSM includes a diagnosis called gender identity dis- order, a sex-related pattern in which people feel that they have been assigned to the wrong sex D. Relatively little is known about racial and other cultural differences in sexuality 1. Sex therapists and sex researchers have only recently begun to attend systematically to the importance of culture and race II. SEXUAL DYSFUNCTIONS A. Sexual dysfunctions are disorders in which people cannot respond normally in key areas of sexual functioning 1. As many as 31 percent of men and 43 percent of women in the United States suffer from such a dysfunction during their lives 2. Sexual dysfunctions typically are very distressing and often lead to sexual frustra- tion, guilt, loss of self-esteem, and interpersonal problems 3.
    [Show full text]
  • Penile Measurements in Normal Adult Jordanians and in Patients with Erectile Dysfunction
    International Journal of Impotence Research (2005) 17, 191–195 & 2005 Nature Publishing Group All rights reserved 0955-9930/05 $30.00 www.nature.com/ijir Penile measurements in normal adult Jordanians and in patients with erectile dysfunction Z Awwad1*, M Abu-Hijleh2, S Basri2, N Shegam3, M Murshidi1 and K Ajlouni3 1Department of Urology, Jordan University Hospital, Amman, Jordan; 2Jordan Center for the Treatment of Erectile Dysfunction, Amman, Jordan; and 3National Center for Diabetes, Endocrinology and Genetics, Amman, Jordan The purpose of this work was to determine penile size in adult normal (group one, 271) and impotent (group two, 109) Jordanian patients. Heights of the patients, the flaccid and fully stretched penile lengths were measured in centimeters in both groups. Midshaft circumference in the flaccid state was recorded in group one. Penile length in the fully erect penis was measured in group two. In group one mean midshaft circumference was 8.9871.4, mean flaccid length was mean 9.371.9, and mean stretched length was 13.572.3. In group two, mean flaccid length was 7.771.3, and mean stretched length was 11.671.4. The mean of fully erect penile length after trimex injection was 11.871.5. In group 1 there was no correlation between height and flaccid length or stretched length, but there was a significant correlation between height and midpoint circumference, flaccid and stretched lengths, and between stretched lengths and midpoint circumference. In group 2 there was no correlation between height and flaccid, stretched, or fully erect lengths. On the other hand, there was a significant correlation between the flaccid, stretched and fully erect lengths.
    [Show full text]
  • Erectile Dysfunction and Premature Ejaculation
    GUIDELINES ON MALE SEXUAL DYSFUNCTION: Erectile Dysfunction and Premature Ejaculation (Text update April 2014) K. Hatzimouratidis (chair), I. Eardley, F. Giuliano, D. Hatzichristou, I. Moncada, A. Salonia, Y. Vardi, E. Wespes Eur Urol 2006 May;49(5):806-15 Eur Urol 2010 May;57(5):804-14 Eur Urol 2012 Sep;62(3):543-52 ERECTILE DYSFUNCTION Definition, epidemiology and risk factors Erectile dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sex- ual performance. Although ED is a benign disorder, it affects physical and psychosocial health and has a significant impact on the quality of life (QoL) of sufferers and their partners. There is increasing evidence that ED can be an early mani- festation of coronary artery and peripheral vascular disease; thus, ED should not be regarded only as a QoL issue but also as a potential warning sign of cardiovascular disease includ- ing lack of exercise, obesity, smoking, hypercholesterolaemia, and the metabolic syndrome. The risk of ED may be reduced by modifying these risk factors, particularly taking exercise or losing weight. Another risk factor for ED is radical prostatec- tomy (RP) in any form (open, laparoscopic, or robotic) because of the risk of cavernosal nerve injury, poor oxygenation of the corpora cavernosa, and vascular insufficiency. 130 Male Sexual Dysfunction Diagnosis and work-up Basic work-up The basic work-up (minimal diagnostic evaluation) outlined in Fig. 1 must be performed in every patient with ED. Due to the potential cardiac risks associated with sexual activity, the three Princeton Consensus Conference stratified patients with ED wanting to initiate, or resume, sexual activity into three risk categories.
    [Show full text]
  • Delayed Ejaculation & Anorgasmia
    Delayed ejaculation & anorgasmia EMMANUELE A. JANNINI Chair of Endocrinology & Sexual Medicine Tor Vergata University of Rome, Italy It Soc Androl & Sex Med – President-elect Taxonomy of ejaculatory disorders Epidemiology of ejaculatory disorders 25 a) timing 20 – PREMATURE EJACULATION 15 – DELAYED EJACULATION 10 Percentage 5 b) modality 0 E N IA R PE DE IO M AS ‐ RETROGRADE EJACULATION LAT G U R O JAC ‐ ANEJACULATION (impotentia ejaculationis) E AN AN Taxonomy of ejaculatory disorders • EMISSION PHASE DISORDERS: – Retrograde ejaculation • EJACULATION PHASE DISORDERS: – Premature ejaculation – Deficient ejaculation: • Delayed ejaculation • Anejaculation • ORGASM DISORDERS: – Anorgasmia – Postorgasmic illness syndrome Standard Operating Procedures (SOP) in Diagnosis and Treatment of Delayed Ejaculation/Anejaculation ISSM Standards Committee Meeting June 23-25, 2010 Hotel Agneshof Nürnberg, Germany Pierre Assalian Canada Emmanuele A. Jannini Italy Chris G McMahon (Chairman) Australia David Rowland USA Marcel Waldinger (Chairman) The Netherlands DELAYED EJACULATION Delayed ejaculation • Much less frequent than PE • A rare reason for medical help seeking • Underdiagnosed • Undertreated Is DE a disease? • girls are happy… …where is the problem? …but girls are not happy… Why so poor science? • Low prevalence • Few studies • Classically considered A new psychogenic in nature • Classically treated with behavioral therapies challenge • Definition(s) lacking • Etiologies largely unknown for • Pathogenesis obscure • Lack of awareness and Sexual acknowledgements
    [Show full text]
  • (Medical and Mechanical) Treatment of Erectile Dysfunction
    130 SOP Conservative (Medical and Mechanical) Treatment of Erectile Dysfunctionjsm_12023 130..171 Hartmut Porst, MD,* Arthur Burnett, MD, MBA, FACS,† Gerald Brock, MD, FRCSC,‡ Hussein Ghanem, MD,§ Francois Giuliano, MD,¶ Sidney Glina, MD,** Wayne Hellstrom, MD, FACS,†† Antonio Martin-Morales, MD,‡‡ Andrea Salonia, MD,§§ Ira Sharlip, MD,¶¶ and the ISSM Standards Committee for Sexual Medicine *Private Urological/Andrological Practice, Hamburg, Germany; †The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, MD, USA; ‡Division of Urology, University of Western, ON, Canada; §Sexology & STDs, Cairo University, Cairo, Egypt; ¶Neuro-Urology-Andrology Unit, Department of Physical Medicine and Rehabilitation, Raymond Poincaré Hospital, Garches, France; **Instituto H.Ellis, São Paulo, Brazil; ††Department of Urology, Section of Andrology and Male Infertility, Tulane University School of Medicine, New Orleans, LA, USA; ‡‡Unidad Andrología, Servicio Urología Hospital, Regional Universitario Carlos Haya, Málaga, Spain; §§Department of Urology & Urological Reseach Institute (URI), Universiti Vita Saluta San Raffaele, Milan, Italy; ¶¶University of California at San Francisco, San Francisco, CA, USA DOI: 10.1111/jsm.12023 ABSTRACT Introduction. Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male self-esteem and nearly all life domains including interper- sonal, family, and business relationships. Aim. The aim of this study
    [Show full text]
  • The Brain, Erectile Dysfunction, and Sexual Violence John D
    Dignity: A Journal on Sexual Exploitation and Violence Volume 2 Article 6 Issue 3 Freedom from Sexploitation July 2017 The Public eH alth Harms of Pornography: The Brain, Erectile Dysfunction, and Sexual Violence John D. Foubert Oklahoma State University, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/dignity Part of the Civic and Community Engagement Commons, Clinical and Medical Social Work Commons, Cognition and Perception Commons, Cognitive Behavioral Therapy Commons, Community-Based Learning Commons, Community Health Commons, Community Health and Preventive Medicine Commons, Developmental Psychology Commons, Domestic and Intimate Partner Violence Commons, Family, Life Course, and Society Commons, Family Practice Nursing Commons, Health Psychology Commons, Marriage and Family Therapy and Counseling Commons, Medical Humanities Commons, Personality and Social Contexts Commons, Politics and Social Change Commons, Psychoanalysis and Psychotherapy Commons, Public Health and Community Nursing Commons, Public Health Education and Promotion Commons, Social Psychology Commons, Social Work Commons, Sociology of Culture Commons, and the Substance Abuse and Addiction Commons Recommended Citation Foubert, John D. (2017) "The ubP lic Health Harms of Pornography: The rB ain, Erectile Dysfunction, and Sexual Violence," Dignity: A Journal on Sexual Exploitation and Violence: Vol. 2: Iss. 3, Article 6. DOI: 10.23860/dignity.2017.02.03.06 Available at: https://digitalcommons.uri.edu/dignity/vol2/iss3/6https://digitalcommons.uri.edu/dignity/vol2/iss3/6 This Freedom from Sexploitation: An Agenda is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Dignity: A Journal on Sexual Exploitation and Violence by an authorized editor of DigitalCommons@URI.
    [Show full text]
  • Post-Orgasmic Illness Syndrome: a Closer Look
    Indonesian Andrology and Biomedical Journal Vol. 1 No. 2 December 2020 Post-orgasmic Illness Syndrome: A Closer Look William1,2, Cennikon Pakpahan2,3, Raditya Ibrahim2 1 Department of Medical Biology, Faculty of Medicine and Health Sciences, Universitas Katolik Indonesia Atma Jaya, Jakarta, Indonesia 2 Andrology Specialist Program, Department of Medical Biology, Faculty of Medicine, Universitas Airlangga – Dr. Soetomo Hospital, Surabaya, Indonesia 3 Ferina Hospital – Center for Reproductive Medicine, Surabaya, Indonesia Received date: Sep 19, 2020; Revised date: Oct 6, 2020; Accepted date: Oct 7, 2020 ABSTRACT Background: Post-orgasmic illness syndrome (POIS) is a rare condition in which someone experiences flu- like symptoms, such as feverish, myalgia, fatigue, irritabilty and/or allergic manifestation after having an orgasm. POIS can occur either after intercourse or masturbation, starting seconds to hours after having an orgasm, and can be lasted to 2 - 7 days. The prevalence and incidence of POIS itself are not certainly known. Reviews: Waldinger and colleagues were the first to report cases of POIS and later in establishing the diagnosis, they proposed 5 preliminary diagnostic criteria, also known as Waldinger's Preliminary Diagnostic Criteria (WPDC). Symptoms can vary from somatic to psychological complaints. The mechanism underlying this disease are not clear. Immune modulated mechanism is one of the hypothesis that is widely believed to be the cause of this syndrome apart from opioid withdrawal and disordered cytokine or neuroendocrine responses. POIS treatment is also not standardized. Treatments includeintra lymphatic hyposensitization of autologous semen, non-steroid anti-inflamation drugs (NSAIDs), steroids such as Prednisone, antihistamines, benzodiazepines, hormones (hCG and Testosterone), alpha-blockers, and other adjuvant medications.
    [Show full text]
  • Ejaculation Problems3 9
    1 6 Fact Sheet 7 12 2 8 11 Ejaculation Problems3 9 4 10 5 What is ejaculation? 1 Bladder 2 Vas deferens Ejaculation is the release of semen from the penis 3 Urethra at orgasm (sexual climax). When a man is sexually 1 stimulated, the brain sends signals to the genital 6 4 Penis area through nerves in the spinal cord to make the 5 Scrotum 7 12 pelvic muscles contract. 2 8 6 Seminal vesicle 11 7 Rectum At orgasm, waves of muscle contractions transport 3 the sperm, with a small amount of fluid, from the 8 Prostate gland testes through to the vas deferens. The seminal 9 9 Epididymis vesicles and prostate contribute extra fluid to 4 10 Testicle protect the sperm. 10 11 Cowper’s gland 5 This mixture of sperm and fluid (semen) travels 12 Ejaculatory duct along the urethra to the tip of the penis where it is ejaculated (released). What are ejaculation problems? More details about premature ejaculation can be found in a separate1 Bladder Andrology Australia fact Men can experience different kinds of ejaculation sheet. 2 Vas deferens problems, including: 3 Urethra The other ejaculation4 Penis problems are less common • premature ejaculation than premature ejaculation5 Scrotum but can also cause distress for the man and his partner. • retrograde ejaculation 6 Seminal vesicle 7 Rectum • delayed ejaculation (or no ejaculation) What causes ejaculation problems? 8 Prostate gland • painful ejaculation. Ejaculation problems9 Epididymis can have a variety of 10 Testicle How common are ejaculation causes, both physical and psychological. Physical causes include11 Cowper’s some gland illnesses such problems? as diabetes, some 12typesEjaculatory of surgery duct or trauma, some types of inflammation or infection, certain Premature ejaculation is the most common male medicines, and chemical imbalances in the brain sexual problem and affects men of all ages.
    [Show full text]
  • Neurogenic Erectile Dysfunction. Where Do We Stand?
    medicines Review Neurogenic Erectile Dysfunction. Where Do We Stand? Charalampos Thomas 1,* and Charalampos Konstantinidis 2 1 Urology Department, General Hospital of Corinth, 20131 Corinth, Greece 2 Urology & Neurourology Unit, National Rehabilitation Center, Ilion, 13122 Athens, Greece; [email protected] * Correspondence: [email protected] Abstract: Erectile Dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance, causing tremendous effects on both patients and their partners. The pathophysiology of ED remains a labyrinth. The underlying mechanisms of ED may be vasculogenic, neurogenic, anatomical, hormonal, drug-induced and/or psychogenic. Neurogenic ED consists of a large cohort of ED, accounting for about 10% to 19% of all cases. Its diversity does not allow an in-depth clarification of all the underlying mechanisms nor a “one size fits all” therapeutical approach. In this review, we focus on neurogenic causes of ED, trying to elucidate the mechanisms that lie beneath it and how we manage these patients. Keywords: erectile dysfunction (ED); neurogenic; sexual dysfunction (SD); phosphodiesterase type-5 inhibitors (PDE5I); spinal cord injury (SCI); multiple sclerosis (MS) 1. Introduction Erectile dysfunction (ED) is defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance [1]. Besides the obvious, it has tremendous effects on the patient’s psychosocial health, and it affects not only their quality of life but the lives of their partners [2]. Citation: Thomas, C.; Konstantinidis, The pathophysiology of ED remains a labyrinth since many pathways can co-exist, C. Neurogenic Erectile Dysfunction. thus contributing negatively. Where Do We Stand? Medicines 2021, Traditionally ED was divided into three large cohorts, organic, psychogenic and of 8, 3.
    [Show full text]
  • The Lookout Winter 2018
    The Lookout Winter 2018 THE LOOKOUT MANIFEST A Message From the Wheelhouse GUE Fundamentals 2018 Diving Highlights Wreck Profile: Reliance SAS_11 Exploration Report News & Updates THE LOOKOUT Published by: Northern Atlantic Dive Expeditions, Inc. https://northernatlanticdive.com A Message From the Wheelhouse [email protected] Thanks for checking out Issue #11 of The Lookout, our annual newsletter covering wide ranging topics that are historical, Editors-in-Chief: technical, and relevant to our diving community in Massachusetts. This issue includes articles on our GUE Heather Knowles Fundamentals class, and trips to Florida, Kingston, Alexandria David Caldwell Bay and Truk Lagoon! We revisit an oldie, but goodie with a wreck profile on the Reliance. We also share an exploration Copyright © 2018 Northern Atlantic Dive update on our project, the unidentified vessel, SAS_11. Expeditions, Inc. We’d like to thank all our customers and crew for your All Rights Reserved continued support and participation aboard Gauntlet. The 2019 diving season will be an exciting one. We hope that you’ll join us on our adventures whether you are looking for training or just some great wreck diving off the coast of New England! We hope you enjoy this issue of The Lookout! Heather and Dave Issue 11 !1 The Lookout Winter 2018 GUE Fundamentals: Never Too Late! Training pathways for divers entering technical diving used to be straightforward. Most divers progressed through open circuit (OC) technical training beginning with advanced nitrox and decompression procedures courses, followed by trimix training through the two or three levels. With the mainstream market entry and growth of closed-circuit rebreathers (CCR), many open circuit trimix divers moved over to this technology, continuing to dive at their highest level after learning the basic foundational skills of the CCR.
    [Show full text]
  • Smoking and Reproduction
    SMOKING AND REPRODUCTION This fact sheet is for public health professionals and others who want information on the many ways smoking affects reproduction, pregnancy, and the health of the fetus and the mother. WHAT YOU SHOULD KNOW ABOUT SMOKING l Pregnancy complications: Smoking is known to cause ectopic pregnancy, AND REPRODUCTION a condition in which the fertilized egg fails to move to the uterus, or womb, and instead attaches to other organs outside the womb. Ectopic pregnancy For many reasons, men and women who want to have children should not almost always causes the fetus to die and is potentially fatal for the mother. smoke. Studies have long shown that smoking and exposure to tobacco Evidence also suggests that spontaneous abortion, or miscarriage, is smoke are harmful to reproductive health. The latest Surgeon General’s caused by smoking during pregnancy. Report on smoking and health says that tobacco use during pregnancy l Fetal growth: Mothers who smoke during pregnancy are more likely to remains a major preventable cause of disease and death of mother, fetus, deliver babies with low birth weight, even if the babies are full term. and infant, and smoking before pregnancy can reduce fertility. Mothers who smoke during pregnancy are also more likely to deliver their babies early. Low birth weight and preterm delivery are leading causes of THE DANGERS OF SMOKING DURING PREGNANCY infant disability and death. Maternal smoking and exposure to secondhand smoke endanger the health l Fetal development: Smoking during pregnancy can cause tissue damage of the mother and the baby. Each year, about 400,000 infants born in the in the fetus, especially in the lungs and brain.
    [Show full text]